Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $225.69M.
ENTERPRISE VALUE (EV)
$225.69M
AC Immune S.A.
Market Cap
$259.52M
Enterprise Value (EV)
$225.69M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| AC Immune S.A. (ACIU) | $259.52M | $225.69M |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $259.46M | $141.59M |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | $136.07M |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.41M | $243.31M |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $262.65M | $176.63M |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.73M | $233.52M |
| OraSure Technologies, Inc. (OSUR)vs › | $265.41M | $116.92M |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.50M | $216.02M |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $267.03M | $178.94M |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $251.29M | $235.40M |
Market Cap
$259.52M
Total Debt
$0.00
Cash
$33.84M
Enterprise Value
$225.69M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
